2-[2-(2-Aminoethylamino)ethylamino]-1-(diaminomethylidene)guanidine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-[2-(2-Aminoethylamino)ethylamino]-1-(diaminomethylidene)guanidine
• 英文别名: 2-[2-(2-aminoethylamino)ethylamino]-1-(diaminomethylidene)guanidine
• 化学式: C₆H₁₈N₈
• 分子量: 202.26
• InChiKey: FPPLXOMYHDIOKU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.7
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  153
• 氢给体数：
  6
• 氢受体数：
  4

文献信息

• Methods for promoting entry of an agent into a cell
  申请人：THE ROYAL VETERINARY COLLEGE

  公开号：US10238683B2

  公开（公告）日：2019-03-26

  A method for promoting entry of an agent (introduced agent) into a cell, the method comprising the step of complexing the introduced agent in the presence of an entry-promoting agent and then exposing to cells, wherein the entry-promoting agent comprises a linear and/or branched or cyclic polymonoguanide/polyguanidine, polybiguanide, analogue or derivative thereof according to the following Formula 1a & b. The method also provides a means for formation of nanoparticles formed between the entry promoting agent and the introduced agent. wherein: “n”, refers to number of repeating units in the polymer, and n can vary from 2 to 1000, for example from 2 or 5 to 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800 or 900; G1 and G2 independently represent a cationic group comprising biguanide or guanidine, wherein L1, and L2 are directly joined to a Nitrogen atom of the guanide; L1 and L2 are linking groups between the G1 and G2 cationic groups in the polymer and independently represent an aliphatic group containing C1-C40 carbon atoms, for example an alkyl group such as methylene, ethylene, propylene, C4, C5, C6, C7, C8, C9 or C10; C1-C10, -C20, -C30, -C40, -C50 -C60 -C70, -C80, -C90, -C-100, -C110, -C120, -C130 or -C140, alkyl; or a C1-C140 (for example C1, C2, C3, C4, C5, C6, C7, C8, C9 or C10; C1-C10, -C20, -C30, -C40, -C50 -C60, - C70, -C80, -C90, -C100, -C110, -C120, -C130o or -C140), cycloaliphatic, heterocyclic, aromatic, aryl, alkylaryl, arylalkyl, or oxyalkylene radical; or a polyalkylene radical optionally interrupted by one or more, preferably one, oxygen, nitrogen or sulphur atoms, functional groups or saturated or unsaturated cyclic moiety; N and G3 are optional end groups; X can be either present or absent; L3, L4 and X are linking groups between the G4 and G5 cationic groups in the polymer and independently represent an aliphatic group containing C1-C140 carbon atoms, for example an alkyl group such as methylene, ethylene, propylene, C4, C5, C6, C7, C8, C9 or C10; C1-C10, -C20, -C30, -C40, -C50 -C60, -C70, -C80, -C90, -C100, -C110, -C120, -C130 or -C140, alkyl; or L3 and L4 and X can independently be C1-C140 (for example C1, C2, C3, C4, C5, C6, C7, C8, C9 or C10; C1-C10, -C20, -C30, -C40, -C50 -C60, -C70, -C80, -C90, -C100, -C110, -C120, -C130 or -C140), cycloaliphatic, heterocyclic, aromatic, aryl, alkylaryl, arylalkyl, oxyalkylene radicals; or a polyalkylene radical optionally interrupted by one or more, preferably one, oxygen, nitrogen or sulphur atoms, functional groups as well as saturated or unsaturated cyclic moiety; “G4” and “G5” are cationic moieties and can be same or different, and at least one of them is a biguanidine moiety or carbamoylguanidine, and the other moiety may be biguanidine or carbamoylguanidine or amine; and cationic moieties G4 and G5 do not contain single guanidine groups. The entry-promoting agent may comprise homogeneous or heterogeneous mixture of one or more of agents arising from formula 1 a and b, for example polyhexamethylene biguanide (PHMB), polyhexamethylene monoguanide (PHMG), polyethylene biguanide (PEB), polytetramethylene biguanide (PTMB), polyethylene hexamethylene biguanide (PEHMB), polymethylene biguanides (PMB), poly(allylbiguanidnio-co-allylamine), poly(N-vinylbiguanide), polyallybiguanide.

  一种促进药剂（导入药剂）进入细胞的方法，该方法包括使导入药剂在导入促进剂存在下复合，然后暴露于细胞的步骤，其中，导入促进剂包括线性和/或支化或环状的聚单胍/聚胍、聚双胍、类似物或其衍生物，如下式1a和b所示，该方法还提供了在导入促进剂和导入药剂之间形成纳米颗粒的方法。 其中：n"，指聚合物中重复单元的数量，n 可以在 2 到 1000 之间变化，例如从 2 或 5 到 10、20、30、40、50、60、70、80、90、100、150、200、250、300、350、400、450、500、600、700、800 或 900；G1 和 G2 独立地代表包含双胍或胍的阳离子基团，其中 L1 和 L2 直接连接到胍的氮原子上；L1 和 L2 是聚合物中 G1 和 G2 阳离子基团之间的连接基团，独立地代表含有 C1-C40 碳原子的脂肪族基团，例如烷基，如亚甲基、亚乙基、亚丙基、C4、C5、C6、C7、C8、C9 或 C10；C1-C10、-C20、-C30、-C40、-C50 -C60 -C70、-C80、-C90、-C-100、-C110、-C120、-C130 或 -C140 烷基；或 C1-C140 （例如 C1、C2、C3、C4、C5、C6、C7、C8、C9 或 C10；C1-C10、-C20、-C30、-C40、-C50 -C60、-C70、-C80、-C90、-C100、-C110、-C120、-C130o 或 -C140）、环脂族、杂环族、芳香族、芳基、烷芳基、芳烷基或氧亚烷基；或任选被一个或多个（最好是一个）氧、氮或硫原子、官能团或饱和或不饱和环基打断的聚亚烷基；N 和 G3 是任选的末端基团；X 既可以存在，也可以不存在；L3、L4 和 X 是聚合物中 G4 和 G5 阳离子基团之间的连接基团，独立地代表含有 C1-C140 碳原子的脂肪族基团，例如烷基，如亚甲基、亚乙基、亚丙基、C4、C5、C6、C7、C8、C9 或 C10；C1-C10、-C20、-C30、-C40、-C50 -C60、-C70、-C80、-C90、-C100、-C110、-C120、-C130 或-C140 的烷基；或 L3 和 L4 以及 X 可以独立地为 C1-C140 （例如 C1、C2、C3、C4、C5、C6、C7、C8、C9 或 C10；C1-C10、-C20、-C30、-C40、-C50 -C60、-C70、-C80、-C90、-C100、-C110、-C120、-C130 或-C140）、环脂族、杂环族、芳香族、芳基、烷芳基、芳烷基、氧烷基；或任选被一个或多个（最好是一个）氧原子、氮原子或硫原子、官能团以及饱和或不饱和环分子打断的聚亚烷基；"G4 "和 "G5 "是阳离子分子，可以相同或不同，其中至少一个是双胍分子或氨基甲酰基胍，另一个分子可以是双胍或氨基甲酰基胍或胺；阳离子分子 G4 和 G5 不含单个胍基。聚六亚甲基双胍（PEHMB）、聚六亚甲基单胍（PHMG）、聚乙烯双胍（PEB）、 聚四亚甲基双胍（PTMB）、聚乙烯六亚甲基双胍（PEHMB）、聚甲醛双胍（PMB）、 聚烯丙基双胍（N-乙烯基双胍）、聚烯丙基双胍。
• METHODS
  申请人：THE ROYAL VETERINARY COLLEGE

  公开号：US20140242097A1

  公开（公告）日：2014-08-28

  A method for promoting entry of an agent (introduced agent) into a cell, the method comprising the step of complexing the introduced agent in the presence of an entry-promoting agent and then exposing to cells, wherein the entry-promoting agent comprises a linear and/or branched or cyclic polymonoguanide/polyguanidine, polybiguanide, analogue or derivative thereof according to the following Formula 1a & b. The method also provides a means for formation of nanoparticles formed between the entry promoting agent and the introduced agent. wherein: “n”, refers to number of repeating units in the polymer, and n can vary from 2 to 1000, for example from 2 or 5 to 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800 or 900; G 1 and G 2 independently represent a cationic group comprising biguanide or guanidine, wherein L 1 , and L 2 are directly joined to a Nitrogen atom of the guanide; L 1 and L 2 are linking groups between the G 1 and G 2 cationic groups in the polymer and independently represent an aliphatic group containing C 1 -C 40 carbon atoms, for example an alkyl group such as methylene, ethylene, propylene, C 4 , C 5 , C 6 , C 7 , C 8 , C 9 or C 10 ; C 1 -C 10 , -C 20 , -C 30 , -C 40 , -C 50 -C 60 -C 70 , -C 80 , -C 9 0, -C- 100 , -C 110 , -C 120 , -C 130 or -C 140 , alkyl; or a C 1 -C 140 (for example C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 or C 10 ; C 1 -C 10 , -C 20 , -C 30 , -C 40 , -C 50 -C 60 , -C 70 , -C 80 , -C 90 , -C 100 , -C 11 0, -C 120 , -C 130 o or -C 140 ), cycloaliphatic, heterocyclic, aromatic, aryl, alkylaryl, arylalkyl, or oxyalkylene radical; or a polyalkylene radical optionally interrupted by one or more, preferably one, oxygen, nitrogen or sulphur atoms, functional groups or saturated or unsaturated cyclic moiety; N and G 3 are optional end groups; X can be either present or absent; L 3 , L 4 and X are linking groups between the G 4 and G 5 cationic groups in the polymer and independently represent an aliphatic group containing C 1 -C 140 carbon atoms, for example an alkyl group such as methylene, ethylene, propylene, C 4 , C 5 , C 6 , C 7 , C 8 , C 9 or C 10 ; C 1 -C 10 , -C 20 , -C 30 , -C 40 , -C 50 -C 60 , -C 70 , -C 80 , -C 90 , -C 100 , -C 110 , -C 120 , -C 130 or -C 140 , alkyl; or L 3 and L 4 and X can independently be C 1 -C 140 (for example C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 or C 10 ; C 1 -C 10 , -C 20 , -C 30 , -C 40 , -C 50 -C 60 , -C 70 , -C 80 , -C 90 , -C 100 , -C 110 , -C 120 , -C 130 or -C 140 ), cycloaliphatic, heterocyclic, aromatic, aryl, alkylaryl, arylalkyl, oxyalkylene radicals; or a polyalkylene radical optionally interrupted by one or more, preferably one, oxygen, nitrogen or sulphur atoms, functional groups as well as saturated or unsaturated cyclic moiety; “G 4 ” and “G 5 ” are cationic moieties and can be same or different, and at least one of them is a biguanidine moiety or carbamoylguanidine, and the other moiety may be biguanidine or carbamoylguanidine or amine; and cationic moieties G 4 and G 5 do not contain single guanidine groups. The entry-promoting agent may comprise homogeneous or heterogeneous mixture of one or more of agents arising from formulae 1 a and b, for example polyhexamethylene biguanide (PHMB), polyhexamethylene monoguanide (PHMG), polyethylene biguanide (PEB), polytetramethylene biguanide (PTMB), polyethylene hexamethylene biguanide (PEHMB), polymethylene biguanides (PMB), poly(allylbiguanidnio-co-allylamine), poly(N-vinylbiguanide), polyallybiguanide.
• COMPOSITION AND METHODS FOR COMBATING ANTIBACTERIAL RESISTANT BACTERIA
  申请人：BLUEBERRY THERAPEUTICS LIMITED

  公开号：US20160089393A1

  公开（公告）日：2016-03-31

  The present invention provides compositions and methods for sensitizing a bacterium to an antibacterial the method comprising the step of exposing the bacterium, in the presence of an entry-promoting agent, to an agent that inhibits antibacterial resistance. Methods for killing an antibacterial-resistant bacterium comprising the step of exposing the bacterium, in the presence of an entry-promoting agent, to an agent that inhibits antibacterial resistance and exposing the bacterium to an antibacterial are also provided. The methods may also include the step of identifying the bacterium and the antibacterial resistance profile of the bacterium and tailoring the methods accordingly. Exemplary entry promoting agents provided are polyhexamethylene biguanide (PHMB) and polyhexamethyleneguanide (PHMG). Exemplary agents that inhibit antibacterial resistance are agents that bindto and inhibit antibacterial-resistance determinants such as beta-lactamases, PBP2a, NDM-1 and Vim2. Compositions, pharmaceutical compositions/formulations and medical uses thereof are also provided according to the invention.